Koers BioNTech SE Xetra
Aandelen
US09075V1026
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 2,75 mld. 2,93 mld. | Omzet 2025 * | 2,74 mld. 2,93 mld. | Marktkapitalisatie | 19,12 mld. 20,44 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -419 mln. -448 mln. | Nettowinst (verlies) 2025 * | -548 mln. -586 mln. | EV/omzet 2024 * | 2,35 x |
Nettoliquiditeiten 2024 * | 12,67 mld. 13,55 mld. | Nettoliquiditeiten 2025 * | 12,02 mld. 12,85 mld. | EV/omzet 2025 * | 2,59 x |
K/w-verhouding 2024 * |
-43,8
x | K/w-verhouding 2025 * |
-34,7
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,48% |
Recentste transcriptie over BioNTech SE
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 02-06-08 |
Özlem Türeci
FOU | Founder | 57 | 02-06-08 |
Jens Holstein
DFI | Director of Finance/CFO | 60 | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Rudolf Staudigl
BRD | Director/Board Member | 70 | 01-01-22 |
Director/Board Member | 67 | 02-06-08 | |
Helmut Jeggle
CHM | Chairman | 53 | 02-06-08 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,19% | 121 mld. | |
+19,91% | 114 mld. | |
+8,24% | 23,61 mld. | |
-16,19% | 16,55 mld. | |
-13,45% | 16,45 mld. | |
-44,35% | 15,59 mld. | |
+66,67% | 15,19 mld. | |
+2,13% | 13,54 mld. | |
+119,39% | 10,96 mld. |